Gretchen A. Gignac, MD

Associate Professor, Medicine

(617) 638-7002
820 Harrison Ave

Biography

I am a medical oncologist who has clinical and research expertise in genitourinary medical oncology as well as clinical trials. My clinical practice is at Boston Medical Center and includes adult patients with cancers of the prostate, kidney, bladder, testicles and penis, as well as other solid cancers. My treatment expertise is in hormonal agents, chemotherapy, immunotherapy, targeted therapies, radioactive pharmaceuticals, bone targeted therapies, supportive and palliative care. I am also an educator in the Boston University School of Medicine and Boston Medical Center Hematology and Oncology Fellowship Program.

Other Positions

  • Active Staff Privileges, Medicine, Boston Medical Center

Education

  • University of Pennsylvania School of Medicine, MD
  • University of Rochester, BA

Classes Taught

Publications

  • Published on 9/1/2016

    Karantanos T, Karanika S, Gignac G. Uncontrolled diabetes predicts poor response to novel antiandrogens. Endocr Relat Cancer. 2016 Sep; 23(9):691-8. PMID: 27515296.

    Read at: PubMed
  • Published on 4/22/2015

    Gunnarsson O, Basaria S, Gignac GA. Cardiometabolic and skeletal risk factors in black men with prostate cancer starting androgen deprivation therapy. Cancers (Basel). 2015; 7(2):679-87. PMID: 25913100.

    Read at: PubMed
  • Published on 5/20/2011

    Gunnarsson O, Basaria S, Gignac G. The prevalence of metabolic risk factors in black men with prostate cancer undergoing consideration for androgen-deprivation therapy. J Clin Oncol. 2011 May 20; 29(15_suppl):e15082. PMID: 28020432.

    Read at: PubMed
  • Published on 4/8/2011

    Hirsch AE, Cuaron JJ, Janicek MJ, Mui K, Lee RJ, Wang DS, Babayan RK, Zumwalt AC, Gignac GA, Tao W, Ozonoff A, Zietman AL. Anatomic differences after robotic-assisted radical prostatectomy and open prostatectomy: implications for radiation field design. Pract Radiat Oncol. 2011 Apr-Jun; 1(2):115-25. PMID: 24673925.

    Read at: PubMed
  • Published on 4/1/2011

    Ariel E. Hirsch, John J. Cuaron, Milos J. Janicek, Kit Mui, Richard J. Lee, David S. Wang, Richard K. Babayan, Ann C. Zumwalt, Gretchen A. Gignac, Wen Tao, Alexander Ozonoff, Anthony L. Zietman et al. . Anatomic differences after robotic-assisted radical prostatectomy and open prostatectomy: implications for radiation field design. Practical Radiation Oncology. 2011; 1(2):115-125.

  • Published on 5/20/2009

    Chi D, Hirsch AE, Gignac GA. Biochemical failure after radiation therapy for prostate cancer: Racial differences. J Clin Oncol. 2009 May 20; 27(15_suppl):e16071. PMID: 27963037.

    Read at: PubMed
  • Published on 5/20/2009

    Dickstein RJ, Kreshover JE, Milose JC, Gignac GA. Metastatic prostate cancer at diagnosis: Clinical presentation in the post-PSA era. J Clin Oncol. 2009 May 20; 27(15_suppl):e16159. PMID: 27963401.

    Read at: PubMed
  • Published on 4/13/2009

    Morris MJ, Pandit-Taskar N, Carrasquillo J, Divgi CR, Slovin S, Kelly WK, Rathkopf D, Gignac GA, Solit D, Schwartz L, Stephenson RD, Hong C, Delacruz A, Curley T, Heller G, Jia X, O'Donoghue J, Larson S, Scher HI. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol. 2009 May 20; 27(15):2436-42. PMID: 19364960.

    Read at: PubMed
  • Published on 9/1/2008

    Gignac GA, Morris MJ, Heller G, Schwartz LH, Scher HI. Assessing outcomes in prostate cancer clinical trials: a twenty-first century tower of Babel. Cancer. 2008 Sep 1; 113(5):966-74. PMID: 18661513.

    Read at: PubMed
  • Published on 12/1/2007

    Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M, Scher HI. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res. 2007 Dec 1; 13(23):7053-8. PMID: 18056182.

    Read at: PubMed

View 3 more publications: View full profile at BUMC

View all profiles